Company Announcements
Director/PDMR Shareholding
Related Companies
By LSE RNS
GlaxoSmithKline plc (the 'Company')
Transaction notification
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||||||||
|
a) |
Name |
Ms E Walmsley |
||||||||||
|
b) |
Position/status |
Chief Executive Officer |
||||||||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||||||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||||||
|
a) |
Name |
GlaxoSmithKline plc |
||||||||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||||||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||||||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
||||||||||
|
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. |
||||||||||
|
c) |
Price(s) and volume(s) |
|
||||||||||
|
d) |
Aggregated information
Aggregated volume Price |
9,616.827 £15.2750
|
||||||||||
|
e) |
Date of the transaction |
2017-10-12 |
||||||||||
|
f) |
Place of the transaction
|
n/a |
||||||||||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||||||
|
a) |
Name |
Mr R G Connor |
||||||||
|
b) |
Position/status |
President, Global Manufacturing & Supply |
||||||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||||
|
a) |
Name |
GlaxoSmithKline plc |
||||||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
||||||||
|
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. |
||||||||
|
c) |
Price(s) and volume(s) |
|
||||||||
|
d) |
Aggregated information
Aggregated volume Price |
4,378.382 £15.2750
|
||||||||
|
e) |
Date of the transaction |
2017-10-12 |
||||||||
|
f) |
Place of the transaction
|
n/a |
||||||||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||||||
|
a) |
Name |
Mr L Debruyne |
||||||||
|
b) |
Position/status |
President, Global Vaccines |
||||||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||||
|
a) |
Name |
GlaxoSmithKline plc |
||||||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
||||||||
|
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. |
||||||||
|
c) |
Price(s) and volume(s) |
|
||||||||
|
d) |
Aggregated information
Aggregated volume Price |
1,869.387 £15.2750
|
||||||||
|
e) |
Date of the transaction |
2017-10-12 |
||||||||
|
f) |
Place of the transaction
|
n/a |
||||||||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||||||
|
a) |
Name |
Mr S Dingemans |
||||||||
|
b) |
Position/status |
Chief Financial Officer |
||||||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||||
|
a) |
Name |
GlaxoSmithKline plc |
||||||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
||||||||
|
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. |
||||||||
|
c) |
Price(s) and volume(s) |
|
||||||||
|
d) |
Aggregated information
Aggregated volume Price |
8,086.638 £15.2750
|
||||||||
|
e) |
Date of the transaction |
2017-10-12 |
||||||||
|
f) |
Place of the transaction
|
n/a |
||||||||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||||||
|
a) |
Name |
Mr N Hirons |
||||||||
|
b) |
Position/status |
SVP, Global Ethics & Compliance |
||||||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||||
|
a) |
Name |
GlaxoSmithKline plc |
||||||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
||||||||
|
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. |
||||||||
|
c) |
Price(s) and volume(s) |
|
||||||||
|
d) |
Aggregated information
Aggregated volume Price |
1,829.052 £15.2750
|
||||||||
|
e) |
Date of the transaction |
2017-10-12 |
||||||||
|
f) |
Place of the transaction
|
n/a |
||||||||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||||||||
|
a) |
Name |
Mr B McNamara |
||||||||||
|
b) |
Position/status |
CEO, GSK Consumer Healthcare |
||||||||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||||||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||||||
|
a) |
Name |
GlaxoSmithKline plc |
||||||||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||||||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||||||||
|
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs') ISIN: US37733W1053
|
||||||||||
|
b) |
Nature of the transaction |
Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 October 2017 on ADSs held in the Company's 2009 Performance Share Plan. |
||||||||||
|
c) |
Price(s) and volume(s) |
|
||||||||||
|
d) |
Aggregated information
Aggregated volume Price |
2,176.780 $41.02
|
||||||||||
|
e) |
Date of the transaction |
2017-10-12 |
||||||||||
|
f) |
Place of the transaction
|
n/a |
||||||||||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||||||
|
a) |
Name |
Mr D S Redfern |
||||||||
|
b) |
Position/status |
Chief Strategy Officer |
||||||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||||
|
a) |
Name |
GlaxoSmithKline plc |
||||||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
||||||||
|
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. |
||||||||
|
c) |
Price(s) and volume(s) |
|
||||||||
|
d) |
Aggregated information
Aggregated volume Price |
3,248.246 £15.2750
|
||||||||
|
e) |
Date of the transaction |
2017-10-12 |
||||||||
|
f) |
Place of the transaction
|
n/a |
||||||||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||||||
|
a) |
Name |
Ms C Thomas |
||||||||
|
b) |
Position/status |
SVP, HR |
||||||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||||
|
a) |
Name |
GlaxoSmithKline plc |
||||||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
||||||||
|
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. |
||||||||
|
c) |
Price(s) and volume(s) |
|
||||||||
|
d) |
Aggregated information
Aggregated volume Price |
3,992.150 £15.2750
|
||||||||
|
e) |
Date of the transaction |
2017-10-12 |
||||||||
|
f) |
Place of the transaction
|
n/a |
||||||||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||||||||
|
a) |
Name |
Mr P C Thomson |
|||||||||
|
b) |
Position/status |
President, Global Affairs |
|||||||||
|
c) |
Initial notification/ amendment |
Initial notification |
|||||||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||||||||
|
a) |
Name |
GlaxoSmithKline plc |
|||||||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||||||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||||||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
|||||||||
|
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. |
|||||||||
|
c) |
Price(s) and volume(s) |
|
|||||||||
|
d) |
Aggregated information
Aggregated volume Price |
2,363.099 £15.2750
|
|||||||||
|
e) |
Date of the transaction |
2017-10-12 |
|||||||||
|
f) |
Place of the transaction
|
n/a |
|||||||||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||||||
|
a) |
Name |
Mr D E Troy |
||||||||
|
b) |
Position/status |
SVP & General Counsel |
||||||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||||
|
a) |
Name |
GlaxoSmithKline plc |
||||||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||||||
|
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs') ISIN: US37733W1053
|
||||||||
|
b) |
Nature of the transaction |
Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 October 2017 on ADSs held in the Company's 2009 Performance Share Plan. |
||||||||
|
c) |
Price(s) and volume(s) |
|
||||||||
|
d) |
Aggregated information
Aggregated volume Price |
3,601.866 $41.02
|
||||||||
|
e) |
Date of the transaction |
2017-10-12 |
||||||||
|
f) |
Place of the transaction
|
n/a |
||||||||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||||||
|
a) |
Name |
Dr P J T Vallance |
||||||||
|
b) |
Position/status |
President, R&D |
||||||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||||
|
a) |
Name |
GlaxoSmithKline plc |
||||||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
||||||||
|
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. |
||||||||
|
c) |
Price(s) and volume(s) |
|
||||||||
|
d) |
Aggregated information
Aggregated volume Price |
9,294.681 £15.2750
|
||||||||
|
e) |
Date of the transaction |
2017-10-12 |
||||||||
|
f) |
Place of the transaction
|
n/a |
||||||||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||||||
|
a) |
Name |
Mrs V A Whyte |
||||||||
|
b) |
Position/status |
Company Secretary |
||||||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||||
|
a) |
Name |
GlaxoSmithKline plc |
||||||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
||||||||
|
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. |
||||||||
|
c) |
Price(s) and volume(s) |
|
||||||||
|
d) |
Aggregated information
Aggregated volume Price |
480.617 £15.2750
|
||||||||
|
e) |
Date of the transaction |
2017-10-12 |
||||||||
|
f) |
Place of the transaction
|
n/a |
||||||||
This information is provided by RNS
You are here: news > regulatory news
10 Lower Thames St,
London EC3R 6EN